Clinical pharmacology and therapeutics
Application of Physiologically Based Pharmacokinetic Modeling to Inform Dose Selection of Mezigdomide in a Phase I Drug-Drug Interaction Study.
Joseph Burnett, Caroline Sychterz, Jessica Katz, Faisal Shakeel, Jose Silva, Wencong Chen, Aditi Shahane, Xiaomin Wang, Manisha Lamba, Allison Gaudy
Published: 202510.1002/cpt.70082
Abstract
Mezigdomide (MEZI) is an oral, highly potent CELMoD™ agent with promising antitumor and immune-stimulatory activity, optimized for Aiolos and Ikaros degradation. Preclinical evidence suggests MEZI is primarily metabolized by cytochrome P450 (CYP) 3A4…
Preview only. Read the full abstract at the source